Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Atorvastatin · DIN 02475030 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Dormant since 2025-07-22 · brand ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 20 MG · company Laboratoire riva inc. · schedule Prescription

DIN 02475030: Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600034; group id 296; item number 0647; lccId None; manufacturer id RIA Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2179; ministry $0.2179 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475030 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96531

Interchangeable products

AG-Atorvastatin · DIN 02478153 · $0.2179 Ach-Atorvastatin Calcium · DIN 02457768 · $0.2179 Apo-Atorvastatin · DIN 02295288 · $0.2179 Atorvastatin · DIN 02348713 · $0.2179 Atorvastatin · DIN 02545470 · $0.2179 Atorvastatin-20 · DIN 02411369 · $0.2179 Auro-Atorvastatin · DIN 02407264 · $0.2179 Bio-Atorvastatin · DIN 02481197 · $0.2179 Jamp Atorvastatin Calcium · DIN 02504200 · $0.2179 Jamp-Atorvastatin · DIN 02391066 · $0.2179 Lipitor · DIN 02230713 · $0.2179 M-Atorvastatin · DIN 02471175 · $0.2179 Mar-Atorvastatin · DIN 02454025 · $0.2179 Mint-Atorvastatin · DIN 02479516 · $0.2179 Mylan-Atorvastatin · DIN 02392941 · $0.2179 NRA-Atorvastatin · DIN 02476525 · $0.2179 PMS-Atorvastatin · DIN 02477157 · $0.2179 PMSC-Atorvastatin · DIN 02507242 · $0.2179 PRZ-Atorvastatin · DIN 02521563 · $0.2179 Ratio-Atorvastatin · DIN 02350319 · $0.2179 Reddy-Atorvastatin · DIN 02417944 · $0.2179 Sandoz Atorvastatin · DIN 02324954 · $0.2179 Taro-Atorvastatin · DIN 02313715 · $0.2179 Teva-Atorvastatin · DIN 02310902 · $0.2179

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475030

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2025-07-22 — choose a marketed DIN from the same-category list.